Search results
Results from the WOW.Com Content Network
in adults inadequately controlled on their maximally tolerated dose of metformin alone; [5] in adults inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin; [5] in adults already being treated with the combination of empagliflozin and metformin as separate tablets. [5]
Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar loss in urine. [2] Empagliflozin was approved for medical use in the United States and in the European Union in 2014. [13] [23] [24] It is on the World Health Organization's List of Essential Medicines. [25]
To reduce the risk of developing ketoacidosis (a serious condition where the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medications, recommending they be temporarily stopped before scheduled surgery.
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . [5] [6] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).
Medicare enrollees can expect to save $1.5 billion in out-of-pocket costs, HHS said. The list price of Merck's diabetes drug Januvia will be slashed to $113 for a 30-day supply from $527 as of 2023.
In the sugar analogues of dapagliflozin, the β-C series are more active than α-C series so it is critical that the β-configuration is at C-1 for the inhibitory activity. [55] Both dapagliflozin and empagliflozin contain a chlorine (Cl) atom in their chemical structure.
C-glucosides have a different pharmacokinetic profile than o-glucosides (e.g. half-life and duration of action) and are not degraded by the β-glucosidase. The first discovered c-glucoside was the drug dapagliflozin. [1] [14] [15] Dapagliflozin was the first highly selective SGLT-2-inhibitor approved by the European Medicines Agency. [16]
A combined result of 5 RCTs enlisting a total of 238 patients aged 65 or older (mean baseline HbA1c of 8.6%) receiving 100 mg/d of vildagliptin was shown to reduce HbA1c by 1.2%. [46] Another set of 6 combined RCTs involving alogliptin (approved by FDA in 2013) was shown to reduce HbA1c by 0.73% in 455 patients aged 65 or older who received 12. ...